- Home
- A-Z Publications
- Current Drug Safety
- Fast Track Listing
Current Drug Safety - Online First
Description text for Online First listing goes here...
23
results
21 - 23 of 23 results
-
-
Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
Available online: 31 October 2024More LessAim The eventuality of tirzepatide, a binary GIP and GLP- 1 receptor agonist, as a treatment for rotundity and metabolic diseases is addressed in this comprehensive review. Background A definition of tirzepatide is that it is an implicit intervention for rotundity, given its effectualness per the cure-dependent effect. Beyond the beneficial effects on body weight loss, tirzepatide also brings about an improvement in lipid biograph Read More
-
-
-
Facial Hyperpigmentation Following Adalimumab
Authors: Mahjoubi Yasmine Salem, Aouinti Imen, Dahmani Israa, Zgolli Fatma, Charfi Ons and El Aidli SihemAvailable online: 31 October 2024More LessBackground Tumor necrosis factor alpha (TNF-α) inhibitors, such as adalimumab, have significantly advanced the treatment of inflammatory diseases. However, these therapies are associated with various cutaneous adverse reactions. Case Presentation We describe two rare instances of isolated facial hyperpigmentation induced by adalimumab. Both patients presented with asymptomatic, isolated brown macules on the c Read More
-
-
-
The Neuroprotective Action of Resveratrol Against Cognitive Impairments Induced by Lorazepam in Male Rats
Available online: 09 October 2024More LessIntroduction/Aim The study examines how chronic resveratrol administration affects behavioral and neurochemical changes caused by Lorazepam (LZP), a classical anti-anxiety medicine associated with neurodegenerative and neurological problems. Method Forty male rats were placed into four groups: a control group receiving 1% Tween 80, the LZP group receiving 2 mg/kg/day, the Resveratrol group receiving 50 mg/kg/da Read More
-